Proteome Sciences PLC Director/PDMR Shareholding (3433U)
October 23 2017 - 6:00AM
UK Regulatory
TIDMPRM
RNS Number : 3433U
Proteome Sciences PLC
23 October 2017
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences
Fund ("Vulpes") that on 18 and 19 October 2017 it purchased 256,520
and 193,100 ordinary shares of 1p each, respectively, in the
capital of the Company ("Ordinary Shares") at an average price of
3.075p per Ordinary Share (the "Purchase") and on 20 October it
purchased 119,636 ordinary shares of 1p each at a price of 3.15p
per Ordinary Share. Following the Purchase, Vulpes has a total
direct and indirect interest in 55,012,971 equivalent to 18.64% of
Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin
Diggle being a Director of both Vulpes and the Company, he now has
an interest in 55,012,971 Ordinary Shares of the Company
representing 18.64% of the issued share capital of the Company.
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Vulpes Life Sciences Fund
2. Reason for the Notification
a) Position/status PCA of Martin Diggle (NED)
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Proteome Sciences plc
b) LEI n/a
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Financial instrument, type of Ordinary Shares of 1p each
instrument
Identification code GB0003104196
b) Nature of the transaction Purchase
c) Price(s) and volume(s) 256,520 Ordinary Shares at 3p per Ordinary Share
193,100 Ordinary Shares at 3.15p per Ordinary Share
119,636 Ordinary Shares at 3.15p per Ordinary Share
d) Aggregated information:
-- Aggregated volume 569,256 Ordinary Shares of 1p each purchased at an
-- Price average price of 3.1125p per Ordinary Share
e) Date of the transaction 18, 19 & 20 October 2017
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
For further information:
Proteome Sciences plc
Jeremy Haigh, Chief Executive Officer
Tel: +44 (0)20 7043 2116
Ian Pike, Chief Scientific Officer
Stefan Fuhrman, Interim Finance Director
finnCap Limited (Nominated Adviser/Broker)
Geoff Nash/James Thompson Tel: +44 (0)20
7220 0500
Tony Quirke (broking)
IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Herring/Miles Nolan Tel: +44 (0)20
3053 8671
Notes for editors:
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) ) and for the
discovery, validation and assay development of protein biomarkers
(TMTcalibrator(TM) ). The company has its headquarters in London,
UK, with laboratory facilities in Frankfurt, Germany from where the
PS Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein
biomarkers for diagnostic and treatment applications in important
areas of human therapeutics such as cancer, stroke and Alzheimer's
disease, and these are available for license.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHFEIFSDFWSELS
(END) Dow Jones Newswires
October 23, 2017 07:00 ET (11:00 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024